DOI 10.1007/s11060-026-05821-y
MGMT promoter methylation as a molecular biomarker in neuro-oncology: current practices, challenges, and future directions.
Аннотация
PURPOSE: MGMT promoter methylation (MGMTpm) is a well-established molecular biomarker in neuro-oncology. We review current practices, challenges, and future directions for MGMTpm as a biomarker in central nervous system (CNS) tumors.
METHODS
The literature on MGMT function, and MGMTpm clinical significance and testing in CNS tumors was reviewed.
RESULTS
We discuss the biological role of MGMT in DNA repair and the mechanisms by which MGMTpm leads to increased tumor sensitivity to alkylating agents. We summarize the clinical significance of MGMTpm in glioblastoma and its emerging relevance in other CNS tumors. Testing practices using methylation-specific PCR, pyrosequencing, and genome-wide methylation array-based approaches are discussed, along with challenges related to testing variability and "gray-zone" methylation, and emerging technologies such as nanopore sequencing.
CONCLUSIONS
Despite ongoing technical and interpretative challenges, MGMTpm remains a robust and clinically valuable biomarker in neuro-oncology.
Предметные рубрики MeSH
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.